Parasitic Worms and Protozoa

Rook's Textbook of Dermatology: Eighth Edition

Volumn 2, Issue , 2010, Pages 1713-1756

  Vega López, Francisco ^a   Hay, Roderick J ^b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cercarial dermatitis, skin disorders with common aetiology free living cercarial stages of non human schistosomes; Chagas' disease unilateral oedema of eyelids and orbit, Chagas Mazza Roma a's sign; Dracunculiasis, chronic infection of humans due to nematode; Infection with nematodes of other animals; Ivermectin, good responses in loiasis reducing microfilaraemia; Parasite, organism depending on living host one or more of its essential metabolic requirements; Parasitic animals, causing skin disease protozoa, helminth worms, and class nematoda; Parasitic worms and protozoa; Trypanosomiasis protozoa of genus trypanosoma widespread tropical disease trypanosomiasis; Visceral larva migrans toxocariasis

Indexed keywords

EID: 84877702639     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444317633.ch37     Document Type: Chapter

References (270)

1. John DT, Petri WA. Markell and Voge's Medical Parasitology. St Louis, USA: Saunders, 2006.
2. Garcia LS. Diagnostic Medical Parasitology, 5th edn. Washington, DC: American Society For Microbiology, 2007.
3. Cooper RA, Stewart B. A Colour Atlas of Medical Parasitology. Queensland, Australia: Knowledge Books and Software, 2006.
4. Marr J, Nilsen T, Komunieki R. Molecular Parasitology. Amsterdam: Academic Press, 2002.
5. Colley DG, LoVerde PT, Saviolo I. Medical helminthology in the 21st century. Science 2001; 293: 1437-8.
6. Muller R. Worms and Human Disease. Wallingford: CABI Publishing, 2002.
7. Noble ER, Noble GA, eds. Parasitology: the Biology of Animal Parasites, 3rd edn. Philadelphia: Lea and Febiger, 1973.
8. Rogers WP, ed. The Nature of Parasitism. New York: Academic Press, 1962.
9. Schmidt GD, Roberts LS, eds. Foundations of Parasitology, 2nd edn. St Louis: Mosby, 1981.
10. Smyth JD, ed. Introduction to Animal Parasitology, 2nd edn. London: Hodder and Stoughton, 1976.
11. Beaver PC, Jung RC, Cupp EW, eds. Clinical Parasitology, 9th edn. Philadelphia: Lea and Febiger, 1984.
12. Binford CH, Connor DH, eds. Pathology of Tropical and Extraordinary Diseases. Washington, DC: US Government Printing Office, 1976.
13. Cook GC, ed. Parasitic Disease in Clinical Practice. London: Springer-Verlag, 1990.
14. Cook GC, ed. Manson's Tropical Diseases, 20th edn. London: Saunders, 1996.
15. Kettle DS, ed. Medical and Veterinary Entomology. London: Croom-Helm, 1984.
16. Soulsby EJL, ed. Helminths, Arthropods and Protozoa of Domesticated Animals, 7th edn. London: Baillière Tindall, 1982.
17. Waltzer PD, Genta R, eds. Parasitic Infections in the Compromised Host. New York: Marcel Dekker, 1989.
18. Boatin BA, Richards FO Jr. Control of onchocerciasis. Adv Parasitol 2006; 61:349-94.
19. Ewert A, Corredor A, Lightener L et al. Onchocerciasis focus in Colombia: follow up study after 12 years. Am J Trop Med Hyg 1979; 28: 486-91.
20. Brown SG. Onchocercal depigmentation. Trans R Soc Trop Med Hyg 1960; 534:325-9.
21. Hay RJ, Mackenzie CD, Guderian R et al. Onchodermatitis-correlation between skin disease and parasitic load in an endemic focus in Ecuador. Br J Dermatol 1989; 121: 187-98.
22. Beaver PC, Horner GS, Bilos JZ. Zoonotic onchocerciasis in a resident of Illinois and observations on the identification of Onchocerca species. Am J Trop Med Hyg 1974; 23: 595-9.
23. Connor DH, Morrison NE, Kerdel-Vegas F et al. Onchocerciasis. Onchocercal dermatitis, lymphadenitis and elephantiasis in the Ubangi territory. Hum Pathol 1970; 1: 553-79.
24. Gibson DW, Heggie C, Connor DH. Clinical and pathologic aspects of onchocerciasis. Pathol Annu 1980; 15: 195-240.
25. Mackenzie CD. Eosinophil leukocytes in filarial infections. Trans R Soc Trop Med Hyg 1980; 74: 51-8.
26. Connor DH, Gibson DW, Neafie RC et al. Sowda-onchocerciasis in North Yemen. A clinicopathologic study of 18 patients. Am J Trop Med Hyg 1983; 32:123-37.
27. Garate T, Conraths FJ, Harnett W et al. Identification of Onchocerca volvulus collagen as an antigen mainly recognised by antibodies in chronic hyper-reactive onchodermatitis (sowda). Am J Trop Med Hyg 1996; 54: 490-7.
28. Akuffo H, Maasho K, Lavebratt C et al. Ivermectin-induced immunopotentiation in onchocerciasis; recognition of selected antigens following a single dose of ivermectin. Clin Exp Immunol 1996; 103: 244-52.
29. Guderian RH, Mackenzie CD, Proano JR. Onchocerciasis in Ecuador. Absence of microfilaremia. J Trop Med Hyg 1987; 90: 213-4.
30. Murdoch M, Hay RJ, Mackenzie CD et al. A new clinical classification for the skin lesions of onchocerciasis. Br J Dermatol 1993; 129: 260-9.
31. Ezzedine K, Malvy D, Dhaussy I et al. Onchocerciasis-associated limb swelling in a traveler returning from Cameroon. J Travel Med 2006; 13:50-3.
32. Mackenzie CD, Williams JF, O'Day J et al. Onchocerciasis in South-Western Sudan; parasitological and clinical characteristics. Am J Trop Med Hyg 1987; 36:371-82.
33. Nelson GS. Hanging groin and hernia, complications of onchocerciasis. Trans R Soc Trop Med Hyg 1958; 52: 272-5.
34. Guderian RH, Swanson D, Casillo R et al. Onchocerciasis in Ecuador. 1. Prevalence and distribution in the province of Esmeraldas. Trop Med Parasitol 1983; 34:143-8.
35. Prost A, Nebout M, Rougement A. Lepromatous leprosy and onchocerciasis. BMJ 1979; i: 589-90.
36. Brown R, Shannon R. Prevalence, intensity and ocular manifestations of Onchocerca volvulus infection in Dimbelenge, Zaire. Ann Soc Belg Med Trop 1989; 69:137-42.
37. Aziz MA, Diallo S, Diop IM et al. Efficacy and tolerance of ivermectin in human onchocerciasis. Lancet 1982; ii: 171-3.
38. Whitworth JA, Downham MD, Lahai G, Maude GH. A community trial of ivermectin for onchocerciasis in Sierra Leone: compliance and parasitological profiles after three and a half years of intervention. Trop Med Int Health 1996; 1: 52-8.
39. Godfrey-Faussett P, Dow C, Black EM, Bryceson ADM. Ivermectin in the treatment of onchocerciasis in Britain. Trop Med Parasitol 1991; 42: 82-4.
40. Rothova A, van der Lelij A, Stilma JS et al. Side effects of ivermectin in treatment of onchocerciasis. Lancet 1989; i: 1439-41.
41. Mas J, Ascaso C, Escaramis G et al. Reduction in the prevalence and intensity of infection in Onchocerca volvulus microfilariae according to ethnicity and community after 8 years of ivermectin treatment on the island of Bioko, Equatorial Guinea. Trop Med Internat Health 2006; 11: 1082-91.
42. Bryceson ADM, Warrell DA, Pope HM. Dangerous reactions to treatment of onchocerciasis with diethylcarbamazine. BMJ 1977; i: 742-4.
43. Guderian RH, Proano R, Beck B et al. The reduction in microfilarial loads in the skin and eye after nodulectomy in Ecuadorian onchocerciasis. Trop Med Parasitol 1987; 38: 272-8.
44. Hoerauf A, Specht S, Büttner M et al. Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study. Med Microbiol Immunol 2008; 197:295-311.
45. Fischer P, Bamuhiiga J, Büttner DW. Treatment of human Mansonella streptocerca infection with ivermectin. Trop Med Int Health 1997; 2: 191-9.
46. Sasa M, ed. Human Filariasis. A Global Survey of Epidemiology and Control. Baltimore: University Park Press, 1976.
47. Wilson T. Filariasis in Malaya-a general review. Trans R Soc Trop Med Hyg 1961; 55: 154-9.
48. Denham DA, McGreevey PB. Brugian filariasis. Epidemiology and experimental studies. Adv Parasitol 1977; 16: 243-52.
49. Dennis DT, Partono F, Atmosoedjono PS, Saroso JS. Timor filariasis: epidemiologic and clinical features in a defined community. Am J Trop Med Hyg 1976; 25:797-802.
50. Davis BR. Filariasis. Dermatol Clin 1989; 7: 313-21.
51. Feinsod FM, Faris R, Gad A et al. Clinical manifestations of Wucheria bancrofti filariasis in an endemic village in the Nile delta. Ann Soc Belge Med Trop 1987; 67: 259-65.
52. Partono F. Filariasis in Indonesia. Clinical manifestations and basic concepts of treatment and control. Trans R Soc Trop Med Hyg 1984; 78: 9-12.
53. Ciba Foundation. Filariasis. Ciba Found Symp 1987; 127: 1-305.
54. Weil, GJ, Ramzy RMR. Diagnostic tools for filariasis elimination programs. Trends Parasitol 2007; 23: 78-82.
55. Zhong M, McCarthy J, Bierwert L et al. A polymerase chain reaction assay for detection of the parasite Wuchereria bancrofti in human blood. Am J Trop Med Hyg 1996; 54: 357-63.
56. Anonymous. Global programme to eliminate lymphatic filariasis. Weekly Epidemiological Record 2007; 82: 361-80.
57. Forsyth K. New approaches to the control of lymphatic filariasis using diethylcarbamazine. PNG Med J 1987; 30: 189-91.
58. Reddy M, Gill SS, Kalkar SR et al. Oral drug therapy for multiple neglected tropical diseases: a systematic review. JAMA 2007; 298: 1911-24.
59. Moulia-Pelat JP, Nguyen LN, Hascoet H et al. Advantages of an annual single dose of ivermectin 400 micrograms/kg plus diethylcarbamazine for community treatment of bancroftian filariasis. Trans R Soc Trop Med Hyg 1995; 86: 682-5.
60. Addiss DG, Brady MA. Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature. Filaria J 2007; 15; 2.
61. Dandapat MC, Mohapatro SK, Mohanty SS. Filarial lymphoedema and elephantiasis of the lower limb; a review of 44 cases. Br J Surg 1986; 73: 451-3.
62. Takougang I, Meli J, Lamlenn S et al. Loiasis-a neglected and under-estimated affliction: endemicity, morbidity and perceptions in eastern Cameroon. Ann Trop Med Parasitol 2007; 101: 151-60.
63. Davis BR. Filariasis. Dermatol Clin 1989; 7: 313-21.
64. Churchill DR, Morris C, Fakoya A et al. Clinical and laboratory features of patients with loiasis (Loa-loa filariasis) in the UK. J Infect 1996; 33: 103-9.
65. Fain A. Update; les problemes actuel de la loase. Bull World Health Organ 1978; 56: 155-67.
66. Hubler WR, Gregory JF, Knox JM. Loiasis. Arch Dermatol 1973; 108: 835-6.
67. Nutman TB, Reese W, Poindexter RW et al. Immunologic correlates of the hyperresponsive syndrome of loiasis. J Infect Dis 1988; 157: 544-50.
68. Pillay VKG, Kirch E, Kurtzman NA. Glomerulopathy associated with filarial loiasis. JAMA 1973; 225: 179-81.
69. De Silva DJ, Strouthidis NG, Tariq S, Davies N. An unusual cause of acute lid swelling. Eye 2006; 20: 271-2.
70. Richard-Lenoble D, Komhla M, Rupp EA et al. Ivermectin in loiasis and con comitant O. volvulus and M. perstans infection. Am J Trop Med Hyg 1988; 39:480-3.
71. Pion SD, Filipe JA, Kamgno J et al. Microfilarial distribution of Loa loa in the human host: population dynamics and epidemiological implications. Parasitology 2006; 133: 101-9.
72. Elgart ML. Onchocerciasis and dracunculosis. Dermatol Clin 1989; 7: 323-30.
73. Watts SJ. Dracunculiasis in Africa in 1986. Its geographic extent, incidence and at-risk population. Am J Trop Med Hyg 1987; 37: 119-25
74. Ruiz-Tiben E, Hopkins DR. Dracunculiasis (Guinea worm disease) eradication. Adv Parasitol 2006; 61: 275-309.
75. Ilegdodu VA, Christensen BL, Wise RA et al. Age and sex differences in new and recurrent cases of guinea-worm disease in Nigeria. Trans R Soc Trop Med Hyg 1987; 81: 674-6.
76. Muller R. Dracunculus and dracunculiasis. Adv Parasitol 1971; 9: 73-91.
77. Pendse AK, Soni BM, Omprakash R et al. Testicular dracunculosis-a distinct clinical entity. Br J Urol 1982; 54: 56-8.
78. Adeyeba OA. Secondary infections in dracunculiasis. Bacteria and morbidity. Int J Zoonoses 1985; 12: 147-9.
79. Ramdas A. Chronic encysted guinea-worm lesion. Ind Med Gaz 1953; 88: 391-2.
80. Chippaux JP. Mebendazole treatment of dracunculiasis. Trans R Soc Trop Med Hyg 1991; 85: 280-2.
81. Barry M. The tail end of guinea worm-global eradication without a drug or a vaccine. New Eng J Med 2007; 356: 2561-4.
82. Schaffner W. Die Bedeutung der Stabibfektion für die Oxyuriasis. Munch Med Wochenschr 1944; 32: 411-4.
83. Clark RF. Localized urticaria due to Enterobius vermicularis. Arch Dermatol 1961; 84: 1026-9.
84. O'Brien TJ. Paediatric vulvovaginitis. Australas J Dermatol 1995; 36: 216-8.
85. Broadbent V. Children's worms. BMJ 1975; i: 89.
86. Pearson RD, Irons RP, Irons RP Jr. Chronic pelvic peritonitis due to the pinworm Enterobius vermicularis. JAMA 1981; 245: 1340-1.
87. Brugmans JP, Thienpont DC, Van Wijngaarden I et al. Mebendazole in enterobiasis. Radiochemical and pilot clinical study in 1278 subjects. JAMA 1971; 217:313-5.
88. Keumer A, Bundy D. Seventy five years of solicitude. Nature 1989; 337: 114-5.
89. Rochet M, Leyrisse M. The nature and causes of 'hookworm anaemia'. Am J Trop Med Hyg 1966; 15: 1030-2.
90. Borrero J, Restrepo A, Betro D et al. Clinical and laboratory studies on hookworm disease in Colombia. Am J Trop Med Hyg 1961; 10: 735-8.
91. Buckley JJC, Pester FRN. Hookworm infections acquired in Britain. BMJ 1965; ii:106-7.
92. Chaudhry AZ, Longworth DL. Cutaneous manifestations of intestinal helminthic infections. Dermatol Clin 1989; 7: 275-90.
93. Gilles HM, Williams EJW, Ball PAJ. Hookworm infection and anaemia. Q Rev Med 1964; 33: 1-24.
94. Reddy M, Gill SS, Kalkar SR et al. Oral drug therapy for multiple neglected tropical diseases: a systematic review. JAMA 2007; 298: 1911-24.
95. Segarra-Newnham M. Manifestations, diagnosis, and treatment of Strongyloides stercoralis infection. Ann Pharmacother 2007; 41: 1992-2001.
96. Igra-Siegman Y, Kapila R, Sen P et al. Syndrome of hyperinfection with Strongyloides stercoralis. Rev Infect Dis 1981; 3: 397-407.
97. Neva FA. Biology and immunology of human strongyloidiasis. J Infect Dis 1986; 153: 397-406.
98. Burke JA. Strongyloidiasis in childhood. Am J Dis Child 1978; 132: 1130-6.
99. Gill GV, Bell DR. Strongyloides stercoralis infection in former Far East prisoners of war. BMJ 1979; ii: 572-4.
100. Ly MN, Bethel SL, Usmani AS et al. Cutaneous Strongyloides stercoralis infection: an unusual presentation. J Am Acad Dermatol 2003; 49: S157-60.
101. von Kuster LC, Genta RM. Cutaneous manifestations of strongyloidiasis. Arch Dermatol 1988; 124: 1826-30.
102. Lanzafame M, Faggian F, Lattuada E et al. Strongyloidiasis in an HIV-1-infected patient after highly active antiretroviral therapy-induced immune restoration. J Infect Dis 2005; 191: 1027.
103. Pelletier LL, Baker CB, Gamm AA et al. Diagnosis and evaluation of chronic strongyloidiasis in ex-prisoners of war. J Infect Dis 1988; 157: 573-6.
104. Beaver PC, Jung RC, Cupp EW, eds. Clinical Parasitology. Philadelphia: Lea and Febiger, 1984: 281-3.
105. Blackwell V, Vega-Lopez F. Cutaneous larva migrans. Clinical features and management of 44 cases presenting in the returned traveller. Br J Dermatol 2001; 145:434-7.
106. Jelinek T, Maiwald H, Nothdurft HD, Loscher T. Cutaneous larva migrans in travelers. Synopsis of histories, symptoms, and treatment of 98 patients. Clin Infect Dis 1994; 19: 1062-6.
107. Katz R, Ziegler J, Blank H. The natural course of creeping eruption and treatment with thiabendazole. Arch Dermatol 1975; 91: 420-4.
108. Wright DO, Gold EM. Löeffler's syndrome associated with creeping eruption (cutaneous helminthiasis). Arch Intern Med 1946; 75: 303-12.
109. Dourmishev AL, Dourmishev LA, Schwartz RA. Ivermectin: pharmacology and application in dermatology. Int J Dermatol 2005; 44: 981-8.
110. Davis CM, Israel RM. Treatment of creeping eruption with topical thiabendazole. Arch Dermatol 1968; 97: 325-6.
111. Despommier D. Toxocariasis: clinical aspects, epidemiology, medical ecology, and molecular aspects. Clin Microbiol Rev 2003; 16: 265-72.
112. Woodruff AW. Toxocariasis. BMJ 1970; ii: 663-4.
113. Rook A, Staughton R. The cutaneous manifestations of toxocariasis. Dermatologica 1972; 144: 129-43.
114. Beaver PC. Toxocariasis (visceral larva migrans) in relation to tropical eosinophilia. Bull Soc Pathol Exot 1962; 55: 555-76.
115. Heiner DC, Kevy SV. Visceral larva migrans. Report of the syndrome in three siblings. N Engl J Med 1956; 254: 629-36.
116. Shields JA. Ocular toxocariasis: a review. Surv Ophthalmol 1984; 28: 361-81.
117. Glickman LT, Schantz P, Dombroske R et al. Evaluation of serological tests for visceral larva migrans. Am J Trop Med Hyg 1978; 27: 492-8.
118. Li MW, Lin RQ, Chen HH et al. PCR tools for the verification of the specific identity of ascaridoid nematodes from dogs and cats. Mol Cell Probes 2007; 21:349-54.
119. Bhatia V, Sarin SK. Hepatic visceral larva migrans. Evolution of the lesion, diagnosis, and role of high-dose albendazole therapy. Am J Gastroenterol 1994; 89:624-7.
120. Ligon BL. Gnathostomiasis: a review of a previously localized zoonosis now crossing numerous geographical boundaries. Semin Pediatr Infect Dis 2005; 16:137-43.
121. Radomyos P, Daengsvang S. A brief report on Gnathostoma spinigerum specimens obtained from human cases. Southeast Asian J Trop Med Public Health 1987; 18:215-7.
122. Rusnak JM, Lucey DR. Clinical gnathostomiasis. Case report and review of the English-language literature. Clin Infect Dis 1993; 16: 33-50.
123. Bunang T, Comer DS, Punyagupta S. Eosinophilic myeloencephalitis caused by Gnathostoma spinigerum. Neuropathology of nine cases. J Neurol Sci 1970; 10:419-34.
124. Nash TE. Visceral larva migrans and other unusual helminth infections. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's Principles and Practice of Infectious Disease, 5th edn. Edinburgh: Churchill Livingstone, 2000:2965-70.
125. Nontasut P, Bussaratid V, Chullawichit S et al. Comparison of ivermectin and albendazole treatment of gnathostomiasis. Southeast Asian J Trop Med Pub Health 2000; 31: 374-9.
126. Bathrick ME, Mango CA, Mueller JF. Intraocular gnathostomiasis. Ophthalmology 1981; 88: 1293-5.
127. Beaver PC, Orihel TC. Human infection with filariae of animals in the United States. Am J Trop Med Hyg 1965; 14: 1010-29.
128. Beaver PC, Wolfson JS, Waldron MA et al. Dirofilaria ursi like parasites acquired by humans in the northern United States and Canada: report of two cases and brief review. Am J Trop Med Hyg 1987; 37: 357-62.
129. Payan HM. Human infection with Dirofilaria. Arch Dermatol 1978; 114: 593-4.
130. Guitierrez Y. Diagnostic features of zoonotic filariae in tissue sections. Hum Pathol 1984; 15: 514-25.
131. Acha PN, Szyfres B. Zoonoses and Communicable Diseases Common to Man and Animals, Vol. 3, Parasitoses. Washington DC: Pan American Health Organization, 2003.
132. Oppenheim JM, Whims CB, Frisch AW. Trichinosis. Clinical and laboratory observations in a group of 256 cases. Mil Surg 1947; 101: 294-6.
133. Schmitt N, Browner EJ, Simon PC et al. Trichinosis from bear meat and adulterated pork: a major outbreak in British Colombia. Can Med Assoc J 1972; 107:1087-9.
134. Frayha RA. Trichinosis-related polyarteritis nodosa. Am J Med 1981; 71: 307-12.
135. Van Knappen F, Franchimont JH, Verdonk AR et al. Detection of specific immunoglobulins (IgG, IgM, IgA, IgE) and total IgE levels in human trichinosis by means of the enzyme-linked immunosorbent assay (ELISA). Am J Trop Med Hyg 1982; 31: 937-46.
136. Clausen MR, Meyer CN, Krantz C et al. Trichinella infection and clinical diseases. Q J Med 1996; 89: 631-6.
137. Watt G, Silachamroon U. Areas of uncertainty in the management of human trichinellosis: a clinical perspective. Expert Rev Anti Infect Ther 2004; 2: 649-52.
138. Mahmoud AAF, ed. Schistosomiasis. In: Mahmoud AAF, ed. Clinical Tropical Medicine and Communicable Diseases. London: Baillière Tindall, 1987: 1-32.
139. Gonzalez E. Schistosomiasis, cercarial dermatitis and marine dermatitis. Dermatol Clin 1989; 7: 291-300.
140. Sturrock RF. Biology and ecology of human schistosomes. In: Mahmoud AAF, ed. Clinical Tropical Medicine and Communicable Diseases. London: Baillière Tindall, 1987: 249-66.
141. Davis A. Recent advances in schistosomiasis. Q J Med 1986; 58: 95-110.
142. Warren KS, Domingo EO, Cowan RBT. Granuloma formation around schistosome eggs as a manifestation of delayed hypersensitivity. Am J Pathol 1967; 51:735-81.
143. WHO. Atlas of the Global Distribution of Schistosomiasis. Geneva: World Health Organization Parasitic Diseases Programme, 1987.
144. Milligan A, Burns DA. Ectopic cutaneous schistosomiasis and schistosomal ocular inflammatory disease. Br J Dermatol 1988; 119: 793-8.
145. Colley DG, Savage AM, Lewis FA. Host responses induced and elicited by cercariae, schistosomata and cercarial antigen preparations. Am J Trop Med Hyg 1977; 26 (Suppl.): 88-91.
146. Torres VM. Dermatological manifestations of Schistosomiasis mansoni. Arch Dermatol 1976; 112: 1539-42.
147. Adeyemi-Doro FAB, Osoba AO, Junaid TA. Perigenital cutaneous schistosomiasis. Br J Vener Dis 1979; 55: 446-9.
148. Davis-Reed L, Theis JH. Cutaneous schistosomiasis: report of a case and review of the literature. J Am Acad Dermatol 2000; 42: 678-80.
149. MacDonald DM, Morrison DA. Cutaneous ectopic schistosomiasis. BMJ 1976; 2:619-20.
150. Farrell AM, Woodrow D, Bryceson AD et al. Ectopic cutaneous schistosomiasis: extragenital involvement with progressive upward spread. Br J Dermatol 1996; 135: 110-2.
151. Obasi OE. Cutaneous schistosomiasis in Nigeria. An update. Br J Dermatol 1986; 114: 597-602.
152. Mahmoud AAF. Praziquantel for the treatment of helminthic infections. In: Stollerman GH, ed. Advances in Internal Medicine, Vol. 32. Chicago: Year Book, 1987: 419-34.
153. Caffrey CR. Chemotherapy of schistosomiasis: present and future. Curr Opin Chem Biol 2007; 11: 433-9.
154. Baird JK, Wear DJ. Cercarial dermatitis. The swimmer's itch. Clin Dermatol 1987; 5: 88-91.
155. Hoeffler DF. Swimmer's itch. Cutis 1977; 19: 461-7.
156. Rao VG, Dash AP, Agrawal MC et al. Cercarial dermatitis in central India: an emerging health problem among tribal communities. Ann Trop Med Parasitol 2007; 101: 409-11.
157. Knight R, Worms NJ. An outbreak of cercarial dermatitis in Britain. Trans R Soc Trop Med Hyg 1972; 66: 21-4.
158. Hutton RF. Schistosome cercariae as a probable cause of sea bather's eruption. Bull Mar Sci Gulf Coast 1952; 2: 346-8.
159. Bernhardt MJ, Mandojana RM. Sea bathers eruption. Clin Dermatol 1987; 5:101-2.
160. Blair D, Xu ZB, Agatsuma T. Paragonimiasis and the genus Paragonimus. Adv Parasitol 1999; 42: 113-222.
161. Sogandares-Bernal F, Seed JR. American paragonimiasis. Curr Top Comp Pathobiol 1973; 2: 1-56.
162. Dainichi T, Nakahara T, Moroi Y et al. A case of cutaneous paragonimiasis with pleural effusion. Int J Dermatol 2003; 42: 699-702.
163. Sabrio P, Lanzas R, Arrieta G, Arguedas A. Paragonimus mexicanus pericarditis. Report of two cases and review of the literature. J Trop Med Hyg 1995; 98:316-8.
164. Smyth JD, Heath DD. Pathogenesis of larval cestodes in mammals. Helm Abstract 1970; 39: 1-23.
165. Templeton AC. Anatomical and geographical location of human coenurus infection. Trop Geogr Med 1971; 23: 105-8.
166. Oriel TC, Gonzalez F, Beaver PC. Coenurus from neck of Texas woman. Am J Trop Med Hyg 1970; 19: 255-7.
167. Williams PH, Templeton AC. Infection of the eye by tapeworm coenurus. Br J Ophthalmol 1971; 55: 766-9.
168. Wilson VCLC, Wayte DM, Addae RO. Human coenurosis-the first reported case from Ghana. Trans R Soc Trop Med Hyg 1972; 66: 611-7.
169. WHO. Bull World Health Organ 1968; 39: 1-136.
170. Saidi F, Nazarian I. Surgical treatment of hydatid cysts by freezing of cyst wall and instillation of 0.5% silver nitrate solution. N Engl J Med 1971; 284: 1346-50.
171. Horton RF. Chemotherapy of Echinococcus infection in man with albendazole. Trans R Soc Trop Med Hyg 1989; 33: 97-102.
172. Keane JR. Neuro-ophthalmic signs and symptoms of cysticercosis. Arch Ophthalmol 1982; 100: 1445-8.
173. Jampol LM, Caldwell BH, Albert DM. Cysticercus cellulosae in the eyelid. Arch Dermatol 1973; 89: 319-20.
174. Norman SH, Kreutner A Jr. Sparganosis. Clinical and pathologic observations in ten cases. South Med J 1980; 73: 297-300.
175. Taylor RL. Sparganosis in the United States. Report of a case. Am J Clin Pathol 1976; 66: 560-4.
176. Beaver PC, Rolon FA. Proliferating larval cestode in a man in Paraguay. A case report and review. Am J Trop Med Hyg 1981; 30: 625-37.
177. Martinez AJ. Acanthamoebiasis and immunosuppression. A case report. J Neuropathol Exp Neurol 1982; 41: 548-57.
178. Bruce-Chwatt LJ. In: Gilles H, Warrell DA, eds. Bruce-Chwatt's Essential Malariology, 3rd edn. London: Heinemann, 1993.
179. Sowunmi A, Walker O, Salako LA. Pruritus and antimalarial drugs in Africans. Lancet 1989; ii: 213.
180. Miller KD, Lobel HO, Satriale RF et al. Severe cutaneous reactions among American travellers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis. Am J Trop Med Hyg 1986; 35: 451-8.
181. Stamm WP. Amoebiasis in England and Wales. BMJ 1975; ii: 452-3.
182. Walsh JA. Problems in recognition and diagnosis of amoebiasis: estimations of global magnitude of morbidity and mortality. Rev Infect Dis 1986; 8: 228-38.
183. Sergeaunt PG. The reliability of Entamoeba histolytica zymodemes in clinical diagnosis. Parasitol Today 1987; 3: 40-3.
184. Martinez-Palomo A. The pathogenesis of amoebiasis. Parasitol Today 1987; 3:111-8.
185. Paul M, Abeyaratne M. Cutaneous amoebiasis. Br J Surg 1961; 49: 288-91.
186. Leippe M, Andra J, Nickel R et al. Amoebapores, a family of membrano-lytic peptides from cytoplasmic granules of Entamoeba histolytica: isolation, primary structure, and pore formation in bacterial cytoplasmic membranes. Mol Microbiol 1994; 14: 895-904.
187. Patterson M, Schoppe LE. The presentation of amoebiasis. Med Clin North Am 1982; 66: 689-705.
188. Fujita WH, Barr RJ, Gottschalk HR. Cutaneous amoebiasis. Arch Dermatol 1981; 117: 309-10.
189. Phillips SC, Mildvan D, William DC et al. Sexual transmission of enteric protozoa and helminths in a venereal disease clinic population. N Engl J Med 1981; 305:603-6.
190. Allason-Jones E, Mindel A, Sargeaunt P et al. Outcome of untreated infection with Entamoeba histolytica in homosexual men with and without HIV antibody. BMJ 1988: 297: 654-6.
191. Knight R. The chemotherapy of amoebiasis. J Antimicrob Chemother 1980; 6:577-93.
192. Honigberg B. Trichomonads of importance in human medicine. In: Kreier JP, ed. Parasitic Protozoa, Vol. 2. New York: Academic Press, 1978: 275-86.
193. Ogunbanjo BO, Osoba AO. Trichomonal vaginitis in Nigerian women. Trop Geogr Med 1984; 26: 67-74.
194. Brown MT. Trichomoniasis. Practitioner 1972; 209: 639-45.
195. Caterall RD. Trichomonal infection of the genital tract. Med Clin North Am 1972; 56:1203-21.
196. Langley JG, Goldsmith JM, Davies N. Venereal trichomoniasis; role of man. Genitourin Med 1987; 63: 264-7.
197. Lossick JG. Treatment of Trichomonas vaginalis infection. Rev Infect Dis 1982; 4 (Suppl.): S801-8.
198. Fouts AC, Kraus SJ. Trichomonas vaginalis. Reevaluation of its clinical presentation and laboratory diagnosis. J Infect Dis 1980; 141: 137-52.
199. Robbie MO, Sweet RL. Metronidazole. Use in obstetrics and gynecology. A review. Am J Obstet Gynecol 1983; 145: 865-81.
200. Sears SD, O'Hare J. In vitro susceptibility testing of Trichomonas vaginalis to 50 antimicrobial agents. Antimicrob Agents Chemother 1988; 69: 524-5.
201. Foulkes JR. Human trypanosomiasis in Africa. BMJ 1981; 283: 1172-4.
202. Spencer HC, Gibson JJ, Brodsky RE et al. Imported African trypanosomiasis in the United States. Ann Intern Med 1975; 82: 633-8.
203. Greenwood BM, Whittle HC. The pathogenesis of sleeping sickness. Trans R Soc Trop Med Hyg 1980; 74: 716-25.
204. Gelfand M. The early clinical features of rhodesiense trypanosomiasis with special reference to the 'chancre' (local reaction). Trans R Soc Trop Med Hyg 1966; 60:376-9.
205. Merklen FP, Riou MV, Solente G et al. Trypanosomiase cutaneé, type d'érythme annulaire centrifuge avec manifestations ganglionnaires discretes. Bull Soc Fr Dermatol 1956; 63: 424-5.
206. Scott JA, Davidson RN, Moody AH et al. Diagnosing multiple parasitic infections: trypanosomiasis, loiasis and schistosomiasis in a single case. Scand J Infect Dis 1991; 23: 777-80.
207. Greenwood BM. African trypanosomiasis. In: Weatherall DJ, Ledingham JGG, Warrell DA, eds. Oxford Textbook of Medicine, 2nd edn. Oxford: Oxford University Press, 1987.
208. Robertson DHH. The treatment of sleeping sickness (mainly due to Trypanosoma rhodesiense) with melarsoprol. II. An assessment of its curative value. Trans R Soc Trop Med Hyg 1963; 57: 176-83.
209. Foulkes JR. An evaluation of prednisolone as a routine adjunct to the treatment of T. rhodesiense. J Trop Med Hyg 1975; 78: 72-4.
210. Romaña C. Enfermedad de Chagas. Buenos Aires, Argentina: Lopez Libreros Editores, 1963.
211. Pifano F. Aspectos de Medicina Tropical de Venezuela. Caracas: OBE, 1964.
212. Levin MJ, Mesri E, Benarous R et al. Identification of major Trypanosoma cruzi antigenic determinants in chronic Chagas' heart disease. Am J Trop Med Hyg 1989; 41: 530-8.
213. Losavio A, Jones MC, Sanz OP et al. A sequential study of the peripheral nervous system involvement in experimental Chagas' disease. Am J Trop Med Hyg 1989; 41: 539-47.
214. Gallerano RH, Marr JJ, Sosa RR. Therapeutic efficacy of allopurinol in patients with chronic Chagas' disease. Am J Trop Med Hyg 1990; 43: 159-66.
215. Leewenberg J, Bryceson ADM, Mbugua GG et al. The use of the leishmanin test to define transmission in Baringo District, Kenya. E Afr Med J 1983; 60: 81-4.
216. Bryceson ADM. Clinical variations associated with various taxa of Leishmania. In: Coll Int CNRS/INSERM 1984. Montpelier: IMEEE, 1986: 221-8.
217. Lainson R. The American leishmaniases. Some observations on their ecology and epidemiology. Trans R Soc Trop Med Hyg 1983; 77: 569-96.
218. Weatherall DJ, Ledingham JGG, Warrell DA, eds. Oxford Textbook of Medicine, 2nd edn. Oxford: Oxford University Press, 1987.
219. Rioux JA, Groubert JR, Lanotte G et al. Un cas de leishmaniose autochtone de la muqueuse nasale. Les Cahiers D'orl 1980; 15: 423-5.
220. Bellazoug S, Ammar-Khodja A, Belkoid M et al. La leishmaniose cutanée du nord d'Algerie. Bull Soc Pathol Exot Filiales 1985; 75: 615-22.
221. Briffa CV. Cutaneous leishmaniasis in the Maltese Islands. Br J Dermatol 1985; 113: 370-1.
222. Bellazoug S. Une épidemie de leishmaniose cutanée dans la région de M'Sila (Algérie). Bull Soc Pathol Exot 1983; 75: 497-504.
223. Ridley DS. A histological classification of cutaneous leishmaniasis and its geographical expression. Trans R Soc Trop Med Hyg 1980; 74: 515-21.
224. Bowling J, Vega-López F. Lupoid leishmaniasis. Clin Exp Dermatol 2003; 28:683-5.
225. Bryceson ADM. Diffuse cutaneous leishmaniasis in Ethiopia. I. The clinical and histological features of the disease. Trans R Soc Trop Med Hyg 1969; 63: 708-37.
226. Dowlati Y. Cutaneous leishmaniasis. Int J Dermatol 1979; 18: 362-8.
227. Nadim A, Fagih M. The epidemiology of cutaneous leishmaniasis in Isfahan province of Iran. Trans R Soc Trop Med Hyg 1968; 61: 534-49.
228. Rahim GF, Tatar IH. Oriental sore in Iraq. Bull Endem Dis (Baghdad) 1966; 8:29-54.
229. Kozevnikov PK. Two nosological forms of cutaneous leishmaniasis. Am J Trop Med Hyg 1963; 12: 719-24.
230. Sacks DL, Kenney RT, Kreutzer RD et al. Indian kala-azar caused by Leishmania tropica. Lancet 1995; 345: 959-61.
231. Evan-Paz Z, Sagher F. Some basic medical problems illustrated by experiments with cutaneous leishmaniasis. S Afr Med J 1961; 35: 567-81.
232. Barnetson RS, Bryceson ADM. Cutaneous leishmaniasis and leprosy. Trans R Soc Trop Med Hyg 1978; 72: 160-3.
233. Griffiths WA, Dutz W. Repeated tissue sampling with a dental broach. A trial in cutaneous leishmaniasis. Br J Dermatol 1975; 93: 43-5.
234. Vega-López F. Diagnosis of cutaneous leishmaniasis. Curr Opin Infect Dis 2003; 16: 97-101.
235. Bryceson A. Therapy in man. In: Peters W, Killick-Kendrick R, eds. The Leishmaniases in Biology and Medicine, Vol. 2. London: Academic Press, 1987: 56-61.
236. Neva FA, Petersen EA, Corsey R et al. Observations on local heat treatment for cutaneous leishmaniasis. Am J Trop Med Hyg 1984; 33: 800-4.
237. Bassiouny A, El Meshad M, Talaat M et al. Cryosurgery in cutaneous leishmaniasis. Br J Dermatol 1982; 107: 467-74.
238. Currie MA. Treatment of cutaneous leishmaniasis by curettage. BMJ 1983; 287:1053-6.
239. Duperrat B, Puissaant A, Fischer R et al. Leishmaniose cutanée plurifocale traitée par glucantime intralésionelle. Bull Soc Fr Dermatol Syphiligr 1966; 73: 219-20.
240. El-On J, Weinrauch L, Livshin R et al. Topical treatment of recurrent cutaneous leishmaniasis with ointment containing paromomycin and methylbenzathonium chloride. BMJ 1985; 291: 704-5.
241. WHO. The Leishmaniases. Report of WHO Expert Committee. Technical Report Series, 701. Geneva: World Health Organization, 1984.
242. Ballou WR, McClain JB, Gordon DM et al. Safety and efficacy of high dose sodium stibogluconate therapy of American cutaneous leishmaniasis. Lancet 1987; ii: 12-6.
243. Chulay JD, Anzeze EM, Koech DK et al. High dose sodium stibogluconate treatment of cutaneous leishmaniasis in Kenya. Trans R Soc Trop Med Hyg 1983; 77:717-21.
244. Bryceson ADM. Diffuse cutaneous leishmaniasis. II. Treatment. Trans R Soc Trop Med Hyg 1970; 64: 369-79.
245. Lawn SD, Yardley V, Watson J, Vega-López F et al. New World cutaneous leishmaniasis in returned travellers: treatment failures using intravenous sodium stibogluconate. Trans Roy Soc Trop Med Hyg 2004; 97: 443-4.
246. Lainson R, Shaw JJ. Evolution, classification and geographical distribution. In: Peters W, Killick-Kendrick R, eds. The Leishmaniases in Biology and Medicine, Vol. 1. London: Academic Press, 1987: 1-120.
247. Walton BC, Chinel LV, Eguiya V et al. Onset of espundia after many years of occult infection with Leishmania braziliensis. Am J Trop Med Hyg 1973; 22: 696-8.
248. Klotz O, Lindenberg H. The pathology of leishmaniasis of the nose. Am J Trop Med Hyg 1923; 3: 117-41.
249. Walton BC. American cutaneous and mucocutaneous leishmaniasis. In: Peters W, Killick-Kendrick R, eds. The Leishmaniases in Biology and Medicine, Vol. 2. London: Academic Press, 1987: 637-44.
250. Biagi FF. The treatment of Mexican cutaneous leishmaniasis (chicle ulcer). Med Mex 1953; 33: 435-8.
251. Llanos-Cuentas EA, Marsden PD, Lago EL et al. Human mucocutaneous leishmaniasis in Tres Bracos, Bahia-Brazil: an area of Leishmania braziliensis braziliensis infection. III. Cutaneous disease, presentation and evolution. Rev Soc Bras Med Trop 1984; 17: 169-77.
252. Floch PH. Sur deux observations intéressantes de leishmaniose forestière américaine. Bull Soc Path Exot 1954; 47: 509-13.
253. Marsden PD. Mucosal leishmaniasis ('espundia' Escomel, 1911). Trans R Soc Trop Med Hyg 1986; 80: 859-76.
254. Marsden PD, Llanos-Cuentos EA, Lago EL et al. Human mucocutaneous leishmaniasis in Tres Bracos, Bahia-Brazil: an area of Leishmania braziliensis braziliensis transmission. III. Mucosal disease, presentation and initial evolution. Rev Soc Bras Med Trop 1984; 17: 179-86.
255. Marsden PD, Sampaio RN, Carvalho EM et al. High continuous antimony therapy in two patients with unresponsive mucosal lesions. Am J Trop Med Hyg 1985; 34: 710-3.
256. Scarisbrick JJ, Chiodini PL, Vega-López F et al. Clinical features and diagnosis of 42 travellers with cutaneous leishmaniasis. Travel Med Infect Dis 2006; 4: 14-21.
257. Pampiglione S, Manson-Bahr PEC, La Placa M et al. Studies on Mediterranean leishmaniasis. 3. The leishmanin test in kala-azar. Trans R Soc Trop Med Hyg 1975; 69: 60-8.
258. Ho M, Koech DK, Iha DW et al. Immunosuppression in Kenyan visceral leishmaniasis. Clin Exp Immunol 1983; 51: 207-14.
259. Rees PH, Kager PA. Visceral leishmaniasis and postkala-azar dermal leishmaniasis. In: Peters W, Killick-Kendrick R, eds. The Leishmaniases in Biology and Medicine, Vol. 2. London: Academic Press, 1987: 114-22.
260. Kumar PV, Sadeghi E, Torabi S. Kala azar with disseminated dermal leishmaniasis. Am J Trop Med Hyg 1989; 40: 150-3.
261. Rashid JR, Chunge CN, Oster CN et al. Post kala-azar dermal leishmaniasis occurring after long cure of visceral leishmaniasis in Kenya. E Afr Med J 1986; 63: 365-71.
262. Sen Gupta PC, Bhattacharjee B. Histopathology of post kala-azar dermal leishmaniasis. J Trop Med Hyg 1953; 56: 110-6.
263. Haldar JP, Ghose S, Saha KC et al. Cell mediated immune response in Indian kala azar and post-kala-azar dermal leishmaniasis. Infect Immun 1983; 42:702-7.
264. Ho M, Leewenberg J, Mbugua G et al. An enzyme-linked immunosorbent assay (ELISA) for field diagnosis of visceral leishmaniasis. Am J Trop Med Hyg 1983; 32: 943-6.
265. Montalban CK, Martinez-Fernandez R, Calleja JL et al. Visceral leishmaniasis (kala-azar) as an opportunistic infection in patients infected with the human immunodeficiency virus in Spain. Rev Infect Dis 1989; 11: 655-60.
266. Forsyth SF, Lawn SD, Miller RF et al. Multiple dermatofibroma-like lesions in a HIV-positive patient coinfected with visceral leishmaniasis. Br J Dermatol 2003; 148: 185-6.
267. Beverley JKA. Congenital toxoplasma infections. Proc R Soc Med 1960; 53: 111-3.
268. Pollock JL. Toxoplasmosis appearing to be dermatomyositis. Arch Dermatol 1979; 115: 736-7.
269. Topi GC, D'Alessandro L, Catricata C et al. Dermatomyositis-like syndrome due to toxoplasma. Br J Dermatol 1979; 101: 589-91.
270. McCabe RE, Remington JS. Toxoplasma gondii. In: Mandell GL, Douglas RG, Bennett JE, eds. Principles and Practice of Infectious Disease, 2nd edn. New York: Wiley, 1983: 1540-9.